ALEXANDRIA, Va., Nov. 18 -- United States Patent no. 12,473,286, issued on Nov. 18, was assigned to Incyte Corp. (Wilmington, Del.).
"Salts of an FGFR inhibitor" was invented by Zhongjiang Jia (Kennett Square, Pa.), Jiacheng Zhou (Newark, Del.) and Qun Li (Newark, Del.).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to salt forms of the Fibroblast Growth Factor Receptors (FGFR) inhibitor 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one, including methods of preparation thereof, where the compound is useful in the treatment of FGFR mediated diseases such as cancer."
The patent was filed on M...